---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-026064"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:34:57.638304+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma upsizes buyback to $325M, cuts 17% staff, appoints new director

## Summary
- Capital return program increased to $325M; $170M remaining; $155M repurchased to date.
- Discontinuing research investments, reducing headcount by ~17%; inhaled JAK program to be partnered.
- Q4 2022 YUPELRI net sales $19.5M (TBPH implied 35% share), up 27% YoY; total revenue $14.6M.
- Appointed Susannah Gray to Board; William D. Young not standing for re-election; Board declassification proposal at May 2 AGM.
- 2023 guidance: R&D $35-45M, SG&A $45-55M; non-GAAP profit expected in 2H 2023.

## SEC filing metadata
- accession: 0001104659-23-026064
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465923026064/0001104659-23-026064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465923026064/tm237863d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-026064
- JSON: https://secwatch.observer/filing/0001104659-23-026064.json
- Plain text: https://secwatch.observer/filing/0001104659-23-026064.txt

## Key facts
- Executive change
  William D. Young departed as Director at Theravance Biopharma, Inc..
  - Action: decided not to stand for re-election
  - Role: Director
  source text: In addition, on February 26, 2023, William D. Young decided not to stand for re-election as a director at the Company’s next annual general meeting of shareholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465923026064/0001104659-23-026064-index.htm
- Executive change
  Susannah Gray was appointed as Director at Theravance Biopharma, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 26, 2023, Susannah Gray was appointed by the Board of Directors of Theravance Biopharma, Inc. (the “Company”) to serve as a Class II member of the Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465923026064/0001104659-23-026064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.